Phase II Study of Chemoradiotherapy With S-1 and Low-Dose Cisplatin for Inoperable Advanced Gastric Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 1, 2008, Pages 173-179

  Saikawa, Yoshiro ^a   Kubota, Tetsuro ^b   Kumagai, Koshi ^a   Nakamura, Rieko ^a   Kumai, Koichiro ^c   Shigematsu, Naoyuki ^a   Kubo, Atsushi ^a   Kitajima, Masaki ^a   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c Center for Diagnostic and Therapeutic Endoscopy   (Japan)

Author keywords

Chemoradiotherapy; Cisplatin; Gastric cancer; S 1

Indexed keywords

DOSIMETRY; ONCOLOGY; PATHOLOGY; PATIENT MONITORING; TUMORS;

CHEMORADIOTHERAPY; CISPLATIN; GASTRIC CANCER; GIANT TUMORS;

RADIOTHERAPY;

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; FLUOROURACIL; IRINOTECAN; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LOW DRUG DOSE; LYMPH NODE DISSECTION; MALE; NAUSEA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RECOMMENDED DRUG DOSE; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; REMISSION INDUCTION; STOMACH; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR;

EID: 41749093634     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.09.010     Document Type: Article

References (20)

1. Hundahl S.A., Phillips J.L., and Menck H.R. The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy, fifth edition. American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 88 (2000) 921-932
2. Landry J., Tepper J.E., Wood W.C., et al. Patterns of failure following curative resection of gastric cancer. Int J Radiat Oncol Biol Phys 191 (1990) 1357-1362
3. MacDonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-730
4. Ravaud A., Borner M., Schellens J.H., et al. EORTC-ECSG: UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer-An Early Clinical Studies Group (ECSG)/European Organization for Research and Treatment of Cancer (EORTC) phase II trial. Eur J Cancer 37 (2001) 1642-1647
5. Garcia A.A., Leichman C.G., Lenz H.J., et al. Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Oncol 31 (2001) 275-278
6. Rohatgi P.R., Mansfield P.F., Crane C.H., et al. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 107 (2006) 1475-1482
7. Ajani J.A., Winter K., Okawara G.S., et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. J Clin Oncol 24 (2006) 3953-3958
8. Harris B.E., Song R., Soong S.T., et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50 (1990) 197-201
9. Shirasaka T., Shimamoto Y., Ohshimo H., et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7 (1996) 548-557
10. Shirasaka K., Shimamoto Y., and Fukushima M. Inhibition by oxanic acid of gastrointestinal toxicity of 5-fluorourail without loss of its antitumor activity in rats. Cancer Res 53 (1993) 4004-4009
11. Sugimachi K., Maehara Y., Horikoshi N., et al., S-1 Gastrointestinal Cancer Study Group. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 57 (1999) 202-210
12. Sakata Y., Ohtsu A., Horikoshi N., et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34 (1998) 1715-1720
13. Saikawa Y., Akasaka Y., Kanai T., et al. Preoperative combination chemotherapy with S-1 and low dose cisplatin against highly advanced gastric cancer. Oncol Rep 10 (2003) 381-386
14. Takahashi T., Saikawa Y., Yoshida M., et al. A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer. Anticancer Res 26 (2006) 1631-1636
15. Saikawa Y., Kubota T., Takahashi T., et al. Is chemoradiation effective or harmful for stage IV gastric cancer patients?. Oncol Rep 13 (2005) 865-870
16. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. 16th ed. (2001), Kanahara, Tokyo, Japan
17. Official reference of CTC version 2.0: Cancer Therapy Evaluation Program. Common Toxicity Criteria, version 2.0 (1998), Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda
18. Iwahashi M., Nakamori M., Tani M., et al. Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low dose cisplatin: Report of a case. Oncology 61 (2001) 16-22
19. Lowy A.M., Feig B.W., Janjan N., et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 8 (2001) 519-524
20. Ajani J.A., Komaki R., Putnam J.B., et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92 (2001) 279-286